Jon Medved: From Startup Trailblazer to ALS Champion
A Life-Altering Diagnosis for a tech Innovator
Jon Medved, a key player in Israel’s dynamic startup ecosystem, encountered an unforeseen personal challenge when he was diagnosed with Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease. This relentless neurological condition progressively damages motor neurons, resulting in the gradual loss of muscle control and difficulties with speech, movement, and breathing.Unlike the usual early signs of limb weakness seen in most patients, medved’s first symptom was a hoarse voice-an unusual but telling indicator of his illness.
This life-changing news compelled him to immediately resign from his leadership role at OurCrowd, the venture capital firm he founded and nurtured for years. His departure resonated deeply within Israel’s tightly knit “Startup Nation,” underscoring how even those who drive innovation are vulnerable to profound health struggles.
OurCrowd: Pioneering Global Venture capital Access
Medved is celebrated as one of the visionaries who helped transform Israel into a global innovation powerhouse. After moving from California to Israel in his twenties and founding several triumphant tech startups, he shifted gears toward investment. In 2013, he launched OurCrowd-a groundbreaking platform that democratized venture capital by enabling accredited investors worldwide to directly participate in funding rounds for emerging companies.
The platform now boasts over 250,000 accredited investors spanning more than 200 countries-including professionals such as architects and educators-who traditionally lacked entry into startup investing. To date,OurCrowd has supported nearly 500 portfolio companies with around 80 successful exits globally.
Diverse Investments Driving Innovation Forward
- Impossible Foods: Revolutionizing sustainable eating through plant-based meat alternatives that reduce environmental impact worldwide.
- Lemonade: An AI-powered insurance provider transforming customer experience by offering transparent policies with rapid claims processing.
- locusview: Acquired recently for $525 million by Itron; this company delivers advanced digital solutions optimizing utility infrastructure planning and management.
The Strength of israeli Tech Amid Regional Unrest
Despite ongoing geopolitical tensions affecting everyday life-including conflicts impacting Gaza-Israel’s technology sector continues to demonstrate remarkable resilience. In just one recent week alone, Israeli startups secured over $900 million in venture funding rounds. The country currently hosts nearly 110 unicorns (startups valued above $1 billion) and attracted between $16 billion and $17 billion in total venture investments last year across fields like cybersecurity, artificial intelligence (AI), semiconductor manufacturing, enterprise software development, food tech innovations, and healthcare technologies.
Merging Technology With Personal Health Challenges
An inspiring dimension of Medved’s journey is how some startups backed by OurCrowd are now directly supporting him through his battle with ALS:
- D-ID: Develops hyper-realistic digital avatars that capture an individual’s unique voice patterns and facial expressions;
- ElevenLabs: Creates cutting-edge voice AI tools enabling peopel affected by speech impairments due to ALS or other conditions to communicate naturally;
- Together with organizations dedicated to advancing ALS care innovations like the Scott-Morgan Foundation,
these ventures have crafted personalized avatar systems tailored specifically for patients facing progressive communication challenges.
This technology recently empowered Medved-and others living with ALS-to actively participate during virtual meetings using digital twins that replicate thier distinctive mannerisms despite physical limitations caused by disease progression.
A Broader Commitment To healthcare Innovation
Beyond communication aids, OurCrowd has invested extensively-in over seventy healthcare-focused startups-that leverage AI-driven diagnostics or genomic sequencing technologies aimed at enhancing personalized treatment.
An example includes oncohost which employs artificial intelligence algorithms assisting oncologists in selecting immunotherapies precisely matched to individual cancer patient profiles.
Other portfolio companies specialize in managing chronic diseases via wearable devices or remote monitoring platforms improving patient outcomes on a global scale.
A Renewed Perspective Born From Adversity
“Facing serious illness firsthand reshapes your understanding far beyond theoretical knowledge,” reflects Medved on his change from investor into patient advocate.
“It profoundly alters your outlook.”
This new perspective fuels his resolve not only to continue contributing strategically behind the scenes but also publicly champion innovations that enhance lives worldwide-even while stepping back from daily leadership duties at OurCrowd.
A Lasting Impact Beyond Financial Gains
“While our primary role is investing,” emphasizes Medved, “being part of this movement empowering entrepreneurs solving real-world problems fills me with immense pride.”
“My avatar preserves my voice when it fades away,” he shares about embracing emerging technologies extending human connection beyond physical limits.”
